Nomacopan

Akari is on track for start of enrollment by the end of 2023 in the registrational Phase 3 study of nomacopan in pediatric HSCT-TMAAkari is moving forward into a Phase 3 double-blind…

NEW YORK and LONDON, July 06, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and…

NEW YORK and LONDON, May 11, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune…

Akari’s complement and leukotriene inhibitor, nomacopan, demonstrated improved survival (80% vs. 30%) in a preclinical model of traumaA follow-on program relevant to both military and…

NEW YORK and LONDON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan…

Nomacopan eyedrops reduced inflammation more than both standard treatments cyclosporin and the steroid dexamethasone in a model of allergic eye diseaseBuilding on early clinical data in…